Revenue Growth Drivers

No five-year revenue CAGR is reported, and the absence of demonstrated compounding limits evidence that FRSX can scale revenue versus peers.

R&D intensity at 20.8% of revenue suggests continued product development, but peer comparison is weak because monetization and commercial conversion remain unproven.

Capex at 8.3% of revenue indicates limited asset build-out, which can preserve flexibility but also signals a small operating base versus better-scaled peers.

Negative EV-to-sales and negative free-cash-flow yield imply the market is not pricing durable revenue expansion, unlike peers with clearer commercial traction.

Market Tailwinds

The company may benefit from ongoing demand for sensing and automotive safety technologies, but execution evidence is weaker than peers with established OEM adoption.

A negative cash conversion cycle can support working-capital efficiency, yet it does not by itself prove durable market pull or repeatable revenue expansion.

The lack of disclosed segment concentration metrics makes it harder to show diversified demand exposure, leaving growth visibility below better-positioned peers.

Compared with peers that have recurring platform revenue or installed-base expansion, FRSX appears earlier in commercialization and less proven at scale.

Scalability Expansion

High R&D spend can support future product breadth, but the absence of revenue CAGR and margin history limits proof that investment converts into scalable growth.

ROIC of 1.7% is low, indicating weak reinvestment efficiency versus peers that compound capital into larger and more durable revenue bases.

Low capex intensity suggests the model is not capital heavy, but it also implies limited evidence of infrastructure-driven scaling capacity.

Net debt to EBITDA is modest, yet leverage is not the binding issue; the main constraint is the lack of demonstrated commercial scale.

Constraints Limitations

The biggest structural constraint is the absence of proven multi-year revenue compounding, which keeps long-term scalability below peers with validated commercialization.

Very low ROIC suggests reinvestment is not yet producing strong incremental growth, limiting the company’s ability to compound efficiently over time.

Negative valuation and cash-flow metrics reflect weak current monetization, which can constrain future funding capacity relative to stronger peers.

Without disclosed concentration or segment data, it is difficult to evidence diversified scaling, increasing dependence on a narrow set of growth outcomes.

Overall Score

FRSX shows early-stage development activity, but the lack of demonstrated revenue compounding, low reinvestment efficiency, and weak commercialization evidence place its 10-year growth capacity well below stronger peers.

Score Driver: Commercialization Proof